210 related articles for article (PubMed ID: 34067348)
1. CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy.
Magkouta SF; Vaitsi PC; Pappas AG; Iliopoulou M; Kosti CN; Psarra K; Kalomenidis IT
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34067348
[TBL] [Abstract][Full Text] [Related]
2. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
3. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
[TBL] [Abstract][Full Text] [Related]
4. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8
Strachan DC; Ruffell B; Oei Y; Bissell MJ; Coussens LM; Pryer N; Daniel D
Oncoimmunology; 2013 Dec; 2(12):e26968. PubMed ID: 24498562
[TBL] [Abstract][Full Text] [Related]
5. Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas.
Yeung J; Yaghoobi V; Miyagishima D; Vesely MD; Zhang T; Badri T; Nassar A; Han X; Sanmamed MF; Youngblood M; Peyre M; Kalamarides M; Rimm DL; Gunel M; Chen L
Neuro Oncol; 2021 Nov; 23(11):1922-1935. PubMed ID: 33914067
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
[TBL] [Abstract][Full Text] [Related]
7. Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment.
Maldonado MDM; Schlom J; Hamilton DH
Cancer Immunol Immunother; 2023 Oct; 72(10):3349-3362. PubMed ID: 37505292
[TBL] [Abstract][Full Text] [Related]
8. CSF1/CSF1R signaling mediates malignant pleural effusion formation.
Kosti CN; Vaitsi PC; Pappas AG; Iliopoulou MP; Psarra KK; Magkouta SF; Kalomenidis IT
JCI Insight; 2022 Mar; 7(6):. PubMed ID: 35315360
[TBL] [Abstract][Full Text] [Related]
9. Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages.
Zhu M; Bai L; Liu X; Peng S; Xie Y; Bai H; Yu H; Wang X; Yuan P; Ma R; Lin J; Wu L; Huang M; Li Y; Luo Y
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600555
[TBL] [Abstract][Full Text] [Related]
10. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer.
Lv Q; Zhang Y; Gao W; Wang J; Hu Y; Yang H; Xie Y; Lv Y; Zhang H; Wu D; Hu L; Wang J
Pharmacol Res; 2024 Apr; 202():107126. PubMed ID: 38432446
[TBL] [Abstract][Full Text] [Related]
11. Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
Gyori D; Lim EL; Grant FM; Spensberger D; Roychoudhuri R; Shuttleworth SJ; Okkenhaug K; Stephens LR; Hawkins PT
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875321
[TBL] [Abstract][Full Text] [Related]
12. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
[TBL] [Abstract][Full Text] [Related]
13. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.
Cannarile MA; Weisser M; Jacob W; Jegg AM; Ries CH; Rüttinger D
J Immunother Cancer; 2017 Jul; 5(1):53. PubMed ID: 28716061
[TBL] [Abstract][Full Text] [Related]
14. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Zhu Y; Knolhoff BL; Meyer MA; Nywening TM; West BL; Luo J; Wang-Gillam A; Goedegebuure SP; Linehan DC; DeNardo DG
Cancer Res; 2014 Sep; 74(18):5057-69. PubMed ID: 25082815
[TBL] [Abstract][Full Text] [Related]
15. Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF
Ngiow SF; Meeth KM; Stannard K; Barkauskas DS; Bollag G; Bosenberg M; Smyth MJ
Oncoimmunology; 2016 Mar; 5(3):e1089381. PubMed ID: 27141346
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1.
Chen TW; Hung WZ; Chiang SF; Chen WT; Ke TW; Liang JA; Huang CY; Yang PC; Huang KC; Chao KSC
Cancer Lett; 2022 Sep; 543():215795. PubMed ID: 35718267
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of a pexidartinib bioisostere inhibiting CSF1 production and CSF1R kinase activity in human hepatocellular carcinoma.
Awasthi BP; Guragain D; Chaudhary P; Jee JG; Kim JA; Jeong BS
Chem Biol Interact; 2023 Jan; 369():110255. PubMed ID: 36368339
[TBL] [Abstract][Full Text] [Related]
18. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.
Xu J; Escamilla J; Mok S; David J; Priceman S; West B; Bollag G; McBride W; Wu L
Cancer Res; 2013 May; 73(9):2782-94. PubMed ID: 23418320
[TBL] [Abstract][Full Text] [Related]
19. Colony-stimulating factor-1 and colony-stimulating factor-1 receptor co-expression is associated with disease progression in gastric cancer.
Okugawa Y; Toiyama Y; Ichikawa T; Kawamura M; Yasuda H; Fujikawa H; Saigusa S; Ohi M; Araki T; Tanaka K; Inoue Y; Tanaka M; Miki C; Kusunoki M
Int J Oncol; 2018 Aug; 53(2):737-749. PubMed ID: 29767252
[TBL] [Abstract][Full Text] [Related]
20. Macrophage-colony stimulating factor (CSF1) predicts breast cancer progression and mortality.
Richardsen E; Uglehus RD; Johnsen SH; Busund LT
Anticancer Res; 2015 Feb; 35(2):865-74. PubMed ID: 25667468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
